Doctors raise $30 million for cancer treatment AI startup

Pi Health, a startup that deploys artificial intelligence in the field of cancer treatment trials, raised more than $30 million in funding to further develop its technology and tie new partnerships.

Pi Health's platform helps clinical trial researchers recruit cancer patients across the U.S., Brazil, Australia and India, allowing drug makers to draw from a diverse genetic pool. The disease is widespread across all strata of populations around the globe, but less than 5% of adults with cancer enroll in clinical studies — a group Pi Health wants to broaden.

Read more:  FTC examining shortages of cancer treatments and other drugs

The company uses AI to automate tasks such as matching patients with trials, clinical documentation, and adverse event monitoring during the studies. Pi Health says its software simplifies a process that currently entails Excel spreadsheets, paper binders, manual data entry and dozens of piece-meal technology solutions.

"We've created an entirely new infrastructure for the clinical trial process, which has become mired in inefficiencies that impede progress," said chief executive officer Geoffrey Kim.

Read more:  Cancer care, autoimmune disease support and Ozempic: Healthcare trends to watch

Pi Health was founded by physicians Kim, a former deputy director of the Oncology Center of Excellence of the U.S. Food and Drug Administration, and Bobby Reddy, a former faculty member of Harvard Medical School and scientist at Massachusetts General Hospital, where he continues to teach and practice.

Pi Health currently harnesses popular generative AI models, but the physician duo has plans to build their own foundational AI system from the ground up.

"We want to go to places that have never participated in clinical trials," said chief operating officer Reddy.